The Digital Wine Ventures Ltd (ASX: DW8) share price is falling today despite the company’s WINEDEPOT business posting strong yearly and monthly gains.

The Digital Wine share price is currently trading at 18.5 cents, down 5.13% today.

Digital Wine Ventures is engaged in distributing premium wine and has been a key benefactor of the digital disruption to the global wine industry.

It also undertakes bulk wine production and contract wine processing. The company focuses on the Asian retail wine market. Digital Wine enables its customers in China to purchase wine from around the world through their personal computers, tablets, and mobile phones.

Digital Wine results

It’s been a busy month for Digital Wine’s WINEDEPOT brand. WINEDEPOT shipped 25,311 cases in March, up more than 550% on the same month last year (MoM) and 21.3% on February 2021. 

It processed 12,272 orders during March, up 504% MoM and 29.3% on January 2021. This equated to an average of 2.06 cases shipped per order.

It also signed up another 27 suppliers and appointed James Munn as chief operating officer (COO).

But the company had seen rapid drops in revenue from December until January, so the current results – while strong – are recovering on November’s highs, leading to a slightly less exciting results period.

WINEDEPOT’s 27 additional suppliers are almost entirely New Zealand and Australian based, with the majority in South Australia.

Digital Wine Venture’s new COO

Digital Wine says its new COO, James Munn, is a “highly experienced” supply chain professional with more than two decades of experience in the warehousing and logistics sector.

He replaces former COO Steven Alexander, who has taken a general management role at Lineage Logistics.

Digital Wine Venture share price snapshot

The Digital Wine Ventures share price has been a high performer over the past 12 months, rising 1750%. It also increased 54% this month and 362.5% in 2021 so far.

More reading

• Why the Digital Wine (ASX:DW8) share price has surged 31% today
• Why AGL, Digital Wine, REA Group, & Xero shares are charging higher
• Why the Digital Wine (ASX:DW8) share price is on ice
• How eBay has sent the Digital Wine (ASX:DW8) share price up 50%

Motley Fool contributor Lucas Radbourne-Pugh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why is the Digital Wine (ASX:DW8) share price tumbling despite strong results? appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3wTDopt

Peninsula Energy Ltd (ASX: PEN) shares are on the rise today after the company provided a market update. At the time of writing, the Peninsula share price is soaring 8.7% higher to 12.5 cents.

We take a look at the ASX uranium share’s latest announcement below.

What was announced?

The Peninsula share price is charging higher after the company provided an update on the MU1A low-pH field demonstration at its Lance Project in the US state of Wyoming.

Since Peninsula’s last update on 26 February, it reported it has made a number of test modifications that have delivered favourable results.

According to the release, the field demonstrations are “designed to provide key data on pattern configurations, pH adjustment, acid consumption and oxidants ahead of a decision to restart production” at the company’s project.

The latest field demonstration revealed that target pH levels were close to being achieved and the new oxidant was delivering results. This moves the company closer to its plans to recommence uranium production.

Commenting on the progress made, Peninsula’s CEO Wayne Heili said:

We are currently 8 months into the field demonstration and are happy with how it is progressing. Adjustments made since our February update have delivered positive results. We will continue to run the field demonstration through the first half of 2022 and the information gained will be invaluable as the company progresses the Lance Project toward a return to commercial production.

In further news driving the Peninsula share price, the company reported that its pilot uranium recovery circuit has been activated.

With leading world nations increasingly moving to reduce their carbon emissions in an effort to minimise global warming, uranium is gaining more attention as a potential power source. While issues like radioactive waste disposal remain a sticky point, uranium doesn’t release any greenhouse gases. That trend could provide tailwinds for ASX uranium shares such as Peninsula Energy.

Peninsula Energy share price snapshot

Despite today’s surge, the Peninsula share price remains down by nearly 11% over the past 12 months, compared to a gain of 31% on the All Ordinaries Index (ASX: XAO).

Year to date, Peninsula shares are up by around 4%.

More reading

• The Peninsula Energy (ASX:PEN) share price lifted 14% today

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the Peninsula Energy (ASX:PEN) share price is soaring 9% appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/326LZqD

At lunch on Tuesday the S&P/ASX 200 Index (ASX: XJO) has given back the majority of its morning gains and is trading largely flat at 6,977.2 points.

Here’s what has been happening on the market today:

Zip Q3 update impresses

The Zip Co Ltd (ASX: Z1P) share price is rocketing higher today following the release of its third quarter update. During the three months ended 31 March, the buy now pay later provider continued its very strong growth. Thanks to a 195% increase in transaction numbers to 12.4 million and a 114% jump in quarterly transaction volume to $1.6 billion, Zip’s revenue grew 80% to a quarterly record of $114.4 million. The US-based QuadPay business was the star performer once again during the quarter.

Regis buys IGO’s Tropicana stake

The Regis Resources Limited (ASX: RRL) share price is in a trading halt today. It requested the halt whilst it undertakes a $650 million equity raising to fund the purchase of a 30% stake in the Tropicana Gold Project from IGO Ltd (ASX: IGO) for $903 million. The balance will be covered by a new loan facility. Regis notes that the acquisition diversifies its existing production base with a non-operated interest in a high quality, low cost, high margin gold asset. Whereas IGO advised that the divestment will allow it to concentrate on its strategic focus on clean energy.

Cleanaway share price rises

The Cleanaway Waste Management Ltd (ASX: CWY) share price is pushing higher today despite news that its acquisition of Suez Australia’s business for $2.5 billion has been terminated. It appears as though the market was far more positive on its backup acquisition of Suez’s Sydney assets for $500 million. This deal will still go ahead regardless of Suez’s merger with fellow waste management giant Veolia.

Best and worst ASX 200 performers

The best performer on the ASX 200 on Tuesday has been the Zip share price with a 10% gain following its third quarter update. Going the other way, the worst performer has been the Perenti Global Ltd (ASX: PRN) share price with a decline of 2%. This is despite there being no news out of the mining services company today.

More reading

• Why IGO, Orocobre, Splitit, & Zip shares are charging higher
• The Orocobre (ASX:ORE) share price is climbing. Here’s why.
• Zip (ASX:Z1P) share price races 11% higher on record Q3 performance
• Regis Resources (ASX:RRL) announces $900m Tropicana Gold Project acquisition
• 2 ASX 200 shares to buy for dividends

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of ZIPCOLTD FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post ASX 200 flat: Zip rockets, Cleanaway higher, Regis-IGO announce Tropicana deal appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3wSO6gb

The BARD1 Life Sciences Limited (ASX: BD1) share price rocketed 9.71% on opening today after the company signed an agreement with the University of Liverpool.

The agreement is the first step towards licensing BARD1’s blood test, which the company hopes will diagnose novel type 3c diabetes. So far, the test has shown promise in preliminary testing. The ability to diagnose type 3c diabetes and other technology BARD1 currently has in the works may help diagnose pancreatic cancer.

After peaking in early trade at $3.71, the BARD1 share price has since lost ground and is now swapping hands at $3.45, up 2.37% at the time of writing. 

Let’s look closer at today’s announcement from the medical diagnostic company.

New options agreement

The options agreement between BARD1 and the University of Liverpool will evaluate 2 novel protein biomarkers.  In preliminary testing, the protein biomarkers can accurately distinguish type 3c diabetes from type 2 diabetes.

The agreement will allow the company the option to licence the intellectual property and commercialise the blood test. In return, BARD1 will pay a non-material upfront options fee and cover any patient costs incurred by the University.

BARD1 states type 3c diabetes accounts for up to 10% of new diabetes diagnoses, but it is under-diagnosed and poorly managed.

What does this mean for fighting pancreatic cancer?

Diabetes is often linked to the pancreas, where insulin is produced. Those with diabetes either don’t produce enough insulin or don’t respond well to insulin, or a combination of both.

In BARD1’s release, it stated around 10% of type 3c diabetes cases were caused by underlying pancreatic cancer. Thus, being quickly diagnosed specifically with type 3c diabetes can be of vital importance.

There is no test for pancreatic cancer, and it has a 5-year survival rate of just 10%.

One of the risk factors for pancreatic cancer, chronic pancreatitis, is the main causes of type 3c diabetes. Not to mention, a diagnosis of diabetes is another major risk factor for the cancer.

BARD1 is also investigating 2 novel approaches for screening pancreatic cancer using its technology to create a test for the cancer. 

Commentary from management

BARD1 CEO Dr Leearne Hinch commented on the technology’s potential, saying:

Currently no screening test is available for pancreatic cancer and even if there was, it would not be practical or cost-effective to screen the average-risk general population.

BARD1’s approach of developing a much-needed blood test for the detection of type 3c diabetes, which also provides a high-risk group for our screening test for pancreatic cancer, provides an ideal and clinically useful solution for both these global health problems.

BARD1 continues to deliver on its mission to develop non-invasive diagnostic tests that make a real difference to patient health outcomes in critical areas of unmet medical need including Type 3c diabetes and pancreatic cancer.

BARD1 Life Sciences share price snapshot

The BARD1 Life Sciences share price has had a ripper year on the ASX so far.

Currently, it’s up a whopping 422% year-to-date. It’s also up 360% over the last 12 months.

BARD1 has a market capitalisation of around $277 million, with approximately 80 million shares outstanding.  

More reading

• The BARD1 (ASX:BD1) share price eyes record highs after positive research results

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the BARD1 (ASX:BD1) share price shot up 10% today appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3g24g0F

Universal Biosensors Inc (ASX: UBI) shares are soaring today after the company shared news of deals with Deakin and Swinburn. At the time of writing, the Universal Biosensors share price is trading 9.68% higher at 68 cents. 

The deals will see the commercialisation of Universal’s Tn Antigen biosensor as well as the development of other biosensors using the company’s electrochemical platform technology.

Let’s look closer at the announcement made by the biotech company this morning.

What was announced?

The Universal Biosensors share price is having a stellar day after the company announced new agreements between it and Deakin University’s Institute of Frontier Metals (DIFM) and Swinburne University of Technology.

Through the deals, Universal Biosensors aims to create a portable device that can sense and monitor cancer from a finger prick of blood.

The two universities have been working on the company’s electrochemical biosensors and the Tn Antigen cancer biomarker for more than 5 years.

The agreement with DIFM will contract half of DIFM’s Senior Fellow Dr Wren Green’s time and resources.

The deal with Swinburne will contract 80% of Dr Saimon Moraes Silva’s time. Dr Silva will be under the supervision of Swinburne’s School Software and Electrical Engineering and Iverson Health Innovation Research Institute’s Professor Simon Moulton.

Combined, the universities should charge the company no more than $300,000, according to the company’s release.

Commentary from management

Universal Biosensor’s CEO John Sharman commented on the agreements, saying:

The knowledge and resources of DIFM and Swinburne will help deliver [a portable device capable of identifying, staging and monitoring cancer] as well as fast track the development of other biosensors we are working on.

Universal Biosensors share price snapshot

The Universal Biosensors share price is having a good year so far on the ASX, with today’s news just the latest boost.

It’s currently up by nearly 45% year to date. It’s also up a whopping 278% over the last 12 months.

The company has a market capitalisation of around $110 million, with approximately 177 million shares outstanding.

More reading

• Why the Universal Biosensors (ASX:UBI) share price is shooting 36% higher today
• Universal Biosensors (ASX:UBI) share price is lifting today. Here’s why

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Here’s why the Universal Biosensors (ASX:UBI) share price is soaring 10% appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3mFCLv4

The Mineral Commodities Limited (ASX: MRC) share price is edging higher in morning trade, up 1.6%.

Mineral Commodities entered a trading halt yesterday pending today’s announcement. We take a look at the details of the ASX resource share’s announcement below.

What did Mineral Commodities report this morning?

Mineral Commodities shares are moving higher after the company reported it has entered into a non-binding Memorandum of Understanding (MOU) with Swedish-based Superior Graphite Co.

The MOU is the first step towards forming a 50:50 Joint Venture (JV) between the 2 companies. The JV would enable Mineral Commodities to use Superior’s thermal purification facility in Sundsvall, Sweden.

Mineral Commodities plans to use Superior’s electro-thermal purification technology to purify its natural flake graphite. The company will immediately undertake a period of due diligence on the Sundsvall facility. It reported the facility has all the required key infrastructure in place along with experienced operating personnel and management.

According to the release, the JV could produce approximately 15–20,000 tonnes per annum (tpa) of Sustainable Graphite Anode Material. The company intends to sell the product primarily to European battery manufacturers who are looking for supplies outside of China.

Commenting on the MOU, Mineral Commodities Chairman, David Baker said:

The JV would provide MRC with a faster route to vertical integration for greater margin capture, reduced technology risk and capex while maintaining our commitment to produce the most sustainable graphite anode material possible.

Superior’s CEO, Edward Carney added, “We are excited to partner with MRC to leverage our leading intellectual property and existing Sundsvall operations synergistically into the European battery anode market at this crucial time in demand for clean energy materials.”

Mineral Commodities share price snapshot

Mineral Commodities shares are up 21% over the past full year. By comparison, the All Ordinaries Index (ASX: XAO) is up 31% over that same time.

Year-to-date the Mineral Commodities share price is down 13%.

More reading

• Mineral Commodities (ASX:MRC) share price plummets 25% as CEO sacked

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the Mineral Commodities (ASX:MRC) share price is moving higher appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3a9dYue

It was a quiet week for the Mainstream Group Holdings Ltd (ASX: MAI) share price. That was until it suddenly jumped 60% before close on Monday. At the time of writing, the Mainstream share price is up 0.76%. trading at $1.99. 

Mainstream share price jumps on superior takeover 

On March 9, Vistra offered to acquire 100% of Mainstream shares at $1.20 per share. A go-shop period was provisioned to allow Mainstream to seek out competing offers until 11 April. 

On Monday, the company announced that a superior proposal has also emerged from SS&C Technologies Holdings, Inc. (NASDAQ: SSNC) for $2.00 cash per share, a 67% premium to the price per share offered by Vistra. 

Mainstream has notified Vistra, and Vistra has until 16 April to match or offer more favourable terms. 

Mainstream has entered into a Scheme Implementation Deed with SS&C, conditional upon the following: 

• Vistra not exercising its matching right.
• Mainstream terminating its Scheme Implementation Deed with Vistra.
• Mainstream paying a $1.708 million break fee to Vistra. 

Who’s acquiring Mainstream? 

SS&C is the world’s largest hedge fund and private equity administrator. Its business model combines end-to-end expertise across financial services operations within software and solutions. In particular, to service the financial services and healthcare industries. 

The company owns and operates the full technology stack across securities accounting, front-to-back office operations, performance and risk analytics, regulatory reporting, and healthcare information processes. 

Over 18,000 financial services and healthcare organisations around the world manage and account for their investments using SS&C’s products and services. 

SS&C has a history of acquisitions and views Mainstream as an attractive opportunity to accelerate its growth, particularly in the Australian market.

Share price snapshot 

Mainstream is a fund administrator for fund managers, superannuation trustees, and listed companies with a focus on the Asia-Pacific region. The company has over 362 clients and 1,202 funds with over $224 billion in funds under administration.

The Mainstream share price rebounded strongly from its COVID lows of 25 cents to all-time record highs of $1.250 last Wednesday. 

More reading

• Why the Mineral Commodities (ASX:MRC) share price is moving higher
• ANZ (ASX:ANZ) share price dips as bank focuses on AI automation
• Analyst downgrades AstraZeneca stock due to vaccine side effect concerns
• Macquarie (ASX:MQG) just delivered ASX lithium shares a big boost
• Why IGO, Orocobre, Splitit, & Zip shares are charging higher

Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of MainstreamBPO Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the Mainstream (ASX:MAI) share price is up 62% this week appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3sg7K1U

The Australia and New Zealand Banking GrpLtd (ASX: ANZ) share price had dipped slightly after the bank announced its focusing on automating home loan application reviewals and other key processes through artificial intelligence (AI).

The ANZ share price is trading at $28.81, down 0.21% at the time of writing.

ANZ is Australia’s second-largest bank by assets and third-largest by market capitalisation. 

ANZ focused on machine learning outcomes

Investors are often excited by the prospect of the digital revolution enhancing productivity. ANZ’s gains today may reflect the company’s insistence on harnessing the potential of artificial intelligence. 

ANZ is hoping that it can reduce the process of reviewing a home loan application to just four seconds, as a computer scans the application forms, ticks the appropriate boxes, and makes a decision.

The technology now exists for ANZ’s computer programs to make these decisions faster than real-time and improve as they work.

ANZ believes this will improve customer experience, as people will no longer have to enter banks and wait for teams to review their paperwork. It will also lead to potential productivity and revenue increases, through less menial labour. 

ANZ received more than $1.2 billion worth of mortgage applications every day in 2020, with turnaround times averaging 17 days.

What ANZ is saying

ANZ’s chief risk officer (CRO), Jason Humphrey, revealed in ANZ’s BlueNotes podcast that the big-four bank had been using machine learning – the process whereby machines are able to adapt and improve themselves – for more than 20 years.

Machine learning has been [used at] ANZ for 20 years in risk management, in the construct of what we call application scoring; we take profiles of customers [and] we look at how they perform over 18-24 months.

We then determine who’s a good payer and who’s not such a great payer. We then go back and look at the attributes and build statistical models around what are the attributes that help predict that performance and that outcome. So, that’s a pretty good example of machine learning,

Mr Humphrey said some of the techniques such as neural networks and random forests had been around for 20 or 30 years:

“… but because of the complexity of those models, and the position where they are used in an ecosystem, we’ve never had the compute power to be able to run them, say in the construct of real-time decisioning.

More reading

• Why NAB (ASX:NAB) and other bank shares are on watch today
• How this ASX ETF is battling the biggest threat to Australian business growth
• ASX 200 Weekly Wrap: ASX sees 7,000 points once more
• 2 buy-rated ASX dividend shares with generous yields
• Is it time to buy ANZ (ASX:ANZ) at today’s share price?

Motley Fool contributor Lucas Radbourne-Pugh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post ANZ (ASX:ANZ) share price dips as bank focuses on AI automation appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2Rzi1Kd

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Shares of AstraZeneca (NASDAQ: AZN) are under pressure again following an analyst downgrade. Concerns about the pharmaceutical company’s coronavirus vaccine led Argus Research to lower its rating on the stock from buy to hold on Monday morning.

Last Wednesday, the European Medicines Agency (EMA) said unusual blood clots with low blood platelets should be listed as a very rare side effect of AstraZeneca’s COVID-19 vaccine, recently given the trade name Vaxzevria. The risk of death from COVID-19 is many orders of magnitude greater, but delays to Vaxzevria’s European roll-out had already damaged public opinion regarding it. Across the EU and the U.K., around 34 million people have been vaccinated as of April 4, 2021. Over that period, 222 blood clots were reported to the EMA’s side-effect hotline. The vast majority of those were non-fatal.

Vaccine hesitancy in the EU and U.S. is already a problem, and the slightest hint of a dangerous side effect will make it more difficult, if not impossible, for AstraZeneca to earn significant profits from Vaxzevra. That said since the company had already committed to selling the vaccine at cost during the pandemic, and on a permanent not-for-profit basis to low- and middle-income countries, AstraZeneca shareholders don’t have much to worry about in terms of lost profits from Vaxzevra over the long run anyway.

The roll-out of this particular COVID-19 vaccine has been a disappointment, but investors need to remember that AstraZeneca isn’t a vaccine company. It’s an oncology-focused drugmaker and a highly successful one with rapidly rising profits.

Unless cancer patients suddenly begin caring about who markets their therapies, COVID-19 vaccine hesitancy isn’t going to appreciably impact AstraZeneca’s earnings. The company’s product lineup sports a handful of recently approved treatments that could push the company’s bottom line and its stock price steadily higher for years to come.  

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

More reading

• ASX 200 Weekly Wrap: ASX sees 7,000 points once more
• Could AstraZeneca double your money despite vaccine woes?
• Are COVID-19 vaccine worries affecting the CSL (ASX:CSL) share price?

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Analyst downgrades AstraZeneca stock due to vaccine side effect concerns appeared first on The Motley Fool Australia.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

from The Motley Fool Australia https://ift.tt/2QdWoyd

ASX lithium shares are the soup du jour with investors and the sector just got a big upgrade from a top broker.

The analysts at Macquarie Group Ltd (ASX: MQG) upgraded their lithium price forecasts by between 30% and 100% for the next four years after they reassessed the outlook for the commodity.

Their very bullish take on the critical battery ingredient is predicated on the belief that global supply will fall short of demand.

Lithium supply shortfall looming large

“Our bullish EV [electric vehicle] demand outlook sees the lithium market move to deficit in 2022 with material shortages emerging from 2025,” said Macquarie.

“The rise in China spot prices has started to translate through to a recovery in regional lithium prices.

“Despite the strong recovery, we note that all regional prices are still down from the beginning of 2020, except for spodumene and Asia lithium carbonate prices.”

The broker believes this signals further upside to regional prices in the coming months.

ASX lithium shares upgraded to “buy”

Significantly for ASX investors, the upward revision in the lithium forecast prompted Macquarie to upgrade its recommendation on some ASX shares.

The Orocobre Limited (ASX: ORE) share price is one beneficiary as the broker upped its rating on the ASX miner to “outperform”.

Second tailwind for the Orocobre share price

Coincidentally, Orocobre issued an upgrade of its own today too. Management said that the sales price for its lithium carbonate jumped 50% to US$5,853 a tonne in the March quarter compared to the previous quarter.

“Orocobre also advises that prices for the June 2021 quarter are expected to be approximately US$7,400/tonne FOB, subject to shipping schedules,” said the miner.

“This pricing will be the highest pricing received since June 2019 and is expected to result in H2FY21 pricing being approximately 20% higher than prior guidance.”

The Orocobre share price jumped 3.5% to $5.66 in morning trade.

Other ASX lithium shares for your buy list

Another ASX miner that got upgraded to “outperform” by Macquarie is the Galaxy Resources Limited (ASX: GXY) share price.

“GXY’s earnings outlook has been transformed by the material upgrades to our lithium and spodumene pricing outlook,” added Macquarie.

“Our earnings estimates have more than doubled over the next five years, with the increased cash flow reducing debt funding requirements.”

The third lithium miner on Macquarie’s buy list is the Pilbara Minerals Ltd (ASX: PLS) share price. It too got a big earnings boost from the lithium price revision.

Macquarie’s 12-month price target on the Orocobre share price is $7.10 a share. It’s target prices for the Galaxy share price and Pilbara Minerals share price are $4.20 and $1.30, respectively.

More reading

• Why IGO, Orocobre, Splitit, & Zip shares are charging higher
• The Orocobre (ASX:ORE) share price is climbing. Here’s why.
• This beaten-down ASX sector could soon be turning the corner
• Here’s why SEEK (ASX:SEK) and these ASX shares are at 52-week highs
• Orocobre (ASX:ORE) share price rebounds from broker downgrade

Motley Fool contributor Brendon Lau owns shares of Galaxy Resources Limited, Macquarie Group Limited, and Orocobre Limited. Connect with me on Twitter @brenlau.

The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Macquarie (ASX:MQG) just delivered ASX lithium shares a big boost appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3sg5jwi